Prognostic Significance of Long Non Coding RNA ANRIL and SNHG14 in Acute Myeloid Leukemia

Document Type : Research Articles

Authors

1 Department of Clinical Pathology, Faculty of Medicine, Alexandria University, Egypt.

2 Hematology Unit, Faculty of Medicine, Alexandria University, Egypt.

Abstract

Background: Long non-coding RNAs (lnRNAs) play a pivotal role in various malignancies including AML. Therefore, we decided to study both lnRNA ANRIL and lnRNA SNHG14 gene expressions in patients with AML to better understand their role in AML risk development, clinical presentation, and prognosis. Methods: The current prospective study included two hundred participants, 100 AML patients and 100 control subjects. Bone marrow analysis was made to all patients, in addition to gene expression molecular testing of both lnRNA ANRIL and lnRNA SNHG14. Results: Both lnRNA SNHG14 and lnRNA ANRIL showed high expression levels in AML bone marrow samples compared to non-AML subjects and were remarkably associated with lower Complete Remission (OR: 3.449, 95% CI: 1.324-8.985, p=0.011 for ANRIL and OR: 3.955, 95% CI: 1.510-10.356, p=0.005 for SNHG14), Relapse Free Survival (HR=3.504, 95%CI: 1.662-7.387, p=0.001 for ANRIL and HR=4.094, 95%CI: 1.849-9.067, p=0.001 for SNHG14) and Overall Survival (HR=3.353, 95%CI: 1.434-7.839, p=0.005 for ANRIL and HR=3.094, 95%CI: 1.277-7.494, p=0.012 for SNHG14), favouring poor prognostic significance in AML. Conclusion: This suggests that both lnRNA ANRIL and lnRNA SNHG14 could be used in the future as prognostic biomarkers to help in treatment decisions and follow up of AML patients.

Keywords

Main Subjects

Asian Pacific Journal of Cancer Prevention
Volume 22, Issue 12
December 2021
Pages 3763-3771

Files

History

  • Receive Date: 08 August 2021
  • Revise Date: 06 October 2021
  • Accept Date: 15 December 2021

Share

How to cite

Statistics